... G,Gozzelino F, Tonato M: Gemcitabine and cisplatin versus mito-mycin, ifosfamide, and cisplatin in advanced non -small- cell lung cancer: a randomized phase III study of the Italian Lung Cancer Project. ... J Cancer 2001, 94:153-156.2. Non -small CellLungCancer Collaborative Group: Chemotherapyin non smallcelllung cancer: a meta-analysis using updateddata on individual patients from 52 randomized ... Di Costanzo F, Frontini L, Tonato M: Italian Lung Cancer Project. Phase III randomized trial comparingthree platinum-based doublets in advanced non small- cell lung cancer. J Clin Oncol 2002,...
... non -small celllungcancer treated with concurrent chemotherapy and intensity-modulated radiotherapyAnhui Shi, Guangying Zhu*, Hao Wu, Rong Yu, Fuhai Li and Bo XuAbstractBackground: To evaluate ... clinical, dosimetric factors and severe acute radiation pneumonitis (SARP) in patients with locally advanced non -small celllungcancer (LANSCLC) treated with concurrent chemotherapy and intensity-modulated ... standard method forthe management of unresectable locally advanced non- small celllungcancer (NSCLC). Unfortunately, the longersurvival is achieved at the price of greater toxicity of thelung...
... mutations in lungcancer patients.Methods: EGFR mutation status was analyzed by DNA assays, and compared with IHC results in five non -small- cell lungcancer (NSCLC) cell lines and tumor samples ... Non -small- celllungcancer harbouring mutations in the EGFRkinase domain. Clin Transl Oncol 2010, 12:75-80.9. Gazdar AF: Activating and resistance mutations of EGFR in non -small- cell lung cancer: ... epidermal growth factorreceptor mutation-specific antibodies for non -small celllung cancer: immunohistochemistry as a possible screening method for epidermalgrowth factor receptor mutations. J...
... Martinelli1,4*AbstractBackground: Lung cancers consist of four major types that and for clinical-pathological reasons are often dividedinto two broad categories: smallcelllungcancer (SCLC) and non -small celllungcancer ... Schwemberger S, Tomlinson CR, Sartor MA, et al:Ligand-independent regulation of transforming growth factor β1expression andcell cycle progression by the aryl hydrocarbon receptor.Mol Cell Biol ... cancers, and might have a role in other malignancies including vulva, skin, oesophagus, head and neck cancer. HPV has also been speculated to have a role in the pathogenesis of lung cancer. To...
... tumor cells versus stromal cells in non small celllung cancer. Clin Cancer Res 2007, 13:6649-57.24. World Health Organization: Histological Typing of Lungand PleuralTumours. Geneva, Switzerland: ... according to NSCLC histology. LungCancer 2010.31. Donnem T, Al-Saad S, Al-Shibli K, Andersen S, Busund LT, Bremnes RM:Prognostic impact of platelet-derived growth factors in non -small cell lungcancer ... various histologicalsubtypes and stages of lungcancer may help to predictthetoxicityandsusceptibility to future RNA targetedtherapies.Figure 2 Disease-specific survival curves according to miR-155expression...
... approximately 29,000 people died from lung cancer in England and Wales[1] and it is the most com-mon and the most life-threatening form of cancer in Scot-land [2]. Lungcancer is also a major cause ... Staging of small cell and non -small celllung cancer. University of Iowa Virtual Hos-pital; 1999. 6. Hopwood P, Stephens RJ: Symptoms at presentation for treat-ment in patients with lung cancer: ... were randomized into two selections (A and B) ofprogressive, stable and responding health states and toxic-ities. All participants were randomly assigned to rate thefollowing: stable and responding...
... Lung cancer is one of the most common human cancers and the leading cause of cancer death world-wide (1). Lungcancer is generally classified into two histological types, smallcelllungcancer ... sensitivity to gefitinib in non -small celllungcancer cell lines. Mol Cancer Res. 2006; 4(8): 521-8. 102. Taguchi F, Solomon B, Gregorc V, et al. Mass spectrometry to classify non -small- celllungcancer ... growth factor receptor and non -small- celllung cancer. J Med Genet. 2007; 44(3): 166-72. 41. Riely GJ, Pao W, Pham D, et al. Clinical course of patients with non -small celllungcancerand epidermal...
... tumorshrinkage, with no additional toxicity, and gave thepatient the possibility to undergo a lobectomy ratherthan a pneumectomy, with the obvious advantages of aless invasive and more limited surgical ... agentdocetaxel in a patient with advanced non small celllung cancer Ferdinando Riccardi1*, Giuseppe Di Lorenzo1, Carlo Buonerba1, Guglielmo Monaco2, Roberto Monaco3,Mimma Rizzo1, Sarah Scagliarini1, ... obtain a response after the first few cycles should notautomatically discourage to continue treatment.IntroductionIn non -small celllungcancer (NSCLC), mediastinallymphnode involvement comprises...
... non -small celllung cancer. LungCancer 2003,41:1-11.17. Shibamoto Y, Yukawa Y, Tsutsui K, Takahashi M, Abe M: Variation in thehypoxic fraction among mouse tumors of different types, sizes, and sites. ... 75:343-347.11. Baba F, Shibamoto Y, Tomita N, Ikeya-Hashizume C, Oda K, Ayakawa S,Ogino H, Sugie C: Stereotactic body radiotherapy for stage I lung cancer andsmalllung metastasis: evaluation ... non -small- celllung cancer: clinical implications. Radiother Oncol2010, 94:1-11.27. Chen Y, Guo W, Lu Y, Zou B: Dose-individualized stereotactic bodyradiotherapy for T1-3N0 non -small cell lung...
... interruptions to palliate thetoxicity from concurrent chemoradiation for limited smallcell lung cancer decreases survival and disease control. LungCancer 2001,33:249-258.26. Cisplatin, etoposide, and ... morphological characteristics ofpermanent human smallcelllungcancercell lines. J Cancer Res ClinOncol 1987, 113:31-40.16. NCCN guidelines for small- celllung cancer. [http://www.nccn.org/professionals/physician_gls/f_guidelines.asp].17. ... in limited-stage small celllung cancer: facts, questions, prospects. Radiother Oncol 2000, 55:1-9.2. Murray N, Turrisi AT: A review of first-line treatment for small- cell lung cancer. J Thorac...
... Stereotactic Body Rad iotherapy, Oligometastases, Non -Small CellLung Cancer BackgroundNon -small celllungcancer (NSCLC) is the leadingcause of cancer mortality in the United States [1].Patients ... and was postulated to be a poor prognostic factor in lung cancer. Similarly,Bradley et al. demonstrated the prognostic value ofGTV determined on planning CT scans to be associatedwith OS and ... limited stage IV non -small celllung cancer Praveena Cheruvu1, Su K Metcalfe1, Justin Metcalfe1, Yuhchyau Chen1, Paul Okunieff2 and Michael T Milano1*AbstractBackground: Standard therapy...